Please assess the completion status of the following clinical trial:

Trial Title: ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification).~* Age from 18 to 65 years.~* Patient not previously treated.~* Ann Arbor stage I or II.~* ECOG performance status \< 2.~* Normal LDH.~* Negative HIV, HBV and HCV serologies 4 weeks (except after vaccination).~* Having previously signed a written informed consent.~Exclusion Criteria:~* Any other histological type of lymphoma. vAny history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in lymph node may be included.~* Central nervous system or meningeal involvement by lymphoma.~* Contra-indication to any drug contained in the chemotherapy regimens.~* Poor renal function (creatinin level \>150 mmol/l), poor hepatic function (total bilirubin level \>30 mmol/l, transaminases \>2.5 maximum normal level).~* Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l.~* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~* Any serious active disease (according to the investigator's decision).~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~* Pregnant or lactating women~* Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- R-ACVBP (Type: EXPERIMENTAL): addition of rituximab to standard ACVBP chemotherapy
- ACVBP (Type: NO_INTERVENTION): standard ACVBP chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).